Stocktoria
BioNexus Gene Lab Corp BGLC
Nasdaq · XNAS · stock · Services-Medical Laboratories · website · IPO 2020-03-11
BioNexus Gene Lab Corp financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $7.4M | $9.5M | $9.8M | $10.9M | $13.4M |
| Gross profit | $1.1M | $1.3M | $1.3M | $1.3M | $2.3M |
| R&D expense | $50,670 | $47,511 | $54,982 | — | — |
| Operating income | -$3.0M | -$1.6M | -$2.6M | -$291,177 | $1.1M |
| Interest expense | — | — | $13,929 | $12,479 | — |
| Income tax | $0 | -$3,494 | -$21,526 | -$52,310 | -$291,283 |
| Net income | -$3.0M | -$1.6M | -$2.6M | -$355,966 | $751,571 |
| EPS (diluted) | — | $-0.09 | $-0.17 | — | — |
| Operating cash flow | -$1.8M | -$2.1M | -$1.8M | $551,822 | $9,161 |
| Free cash flow | -$1.9M | -$2.3M | -$2.0M | $551,822 | $5,999 |
| Cash & equivalents | $2.5M | $2.9M | — | — | $2.1M |
| Inventory | $676,703 | $1.4M | $1.1M | $977,807 | $1.5M |
| Total assets | $9.3M | $10.4M | $11.4M | $8.7M | $9.6M |
| Total liabilities | $637,856 | $2.1M | $1.7M | $2.1M | $2.4M |
| Shareholders' equity | $8.6M | $8.3M | $9.7M | $6.7M | $7.2M |
Source: SEC EDGAR filings · CIK 0001737523 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.